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chemotherapy and radiotherapy
The prevalence of disease-related malnutrition in patients
with cancer ranges from 40% to 80%, which is the highest of
all hospital groups. This variation in prevalence is the result
of the different definitions of malnutrition used, and it also
depends on tumour type, stage and anticancer treatment.
Malnutrition is associated with negative outcome, including
increased morbidity, poor prognoses and tolerance to treat-
ment, decreased quality of life and increased health-care
costs [1]. Head and neck cancer patients who experience a
weight loss >20% of their total body weight during or
following radiotherapy are at an increased risk of toxicity
and mortality. Stage 3 or 4 disease and smoking more than
20 cigarettes a day should be reason enough for early enteral
feeding. A prophylactic percutaneously placed endoscopic
gastrostomy (PEG) feeding tube is also beneficial when there
is pretreatment weight loss [2].
Nutrition screening is the process of identifying patients
with characteristics commonly associated with nutritional
problems that may require full nutritional assessment.
Screening can be applied to all patients. The malnutrition
screening tool (MST) is a validated, quick and simple nutrition
screening tool. The patient-generated subjective global
assessment (PG-SGA) can be applied for a full nutritional
assessment [1].
The identification of baseline risk factors to assess a
patient’s fragility or ability to tolerate treatment is desirable
to predict outcome of chemotherapy toxicity, not only for
medically unfit patients but also amongst patients with an
apparently good medical condition, since the high inter-indi-
vidual variability in drug exposure remains an unresolved
issue. Chemotherapy-induced DNA damage might become
more cytotoxic to normal tissue in the presence of perturba-
tions of the cellular immune response because of high protein
catabolism and stimulation of acute-phase protein responses
(APPRs). The nutritional and inflammatory status (NIS)
appears to correlate with increased risk of severe haematolog-ical toxicity following anticancer chemotherapy. This status
takes in account (1) C-reactive protein, (2) alpha-1-acid
glycoprotein, (3) albumin and (4) prealbumin: NIS = (1 · 2)/
(3 · 4) [3].
Malnutrition has been associated with changes in drug
disposition, including changes in absorption, protein binding,
hepatic metabolism and renal elimination. In malnourished
patients reduced concentrations of plasma proteins may
significantly increase the likelihood of toxicity from the
administrations of agents that are highly protein-bound, such
as prednisolone, etoposide, teniposide, cisplatin, paclitaxel
and SN-38 [4].
Anticancer treatment can induce a poor nutritional
status by inducing nausea, vomiting and anorexia and
gastrointestinal disorders as mucositis and diarrhoea [4].
Reversible lactose intolerance – associated with diarrhoea,
flatulence and poor nutritional status – is not infrequent
in patients treated with chemotherapy based on 5-fluoro-
uracil (5-FU). Hypolactasia can easily be diagnosed with a
lactose tolerance test. Dietary lactose restriction might
improve tolerability of treatment [5]. Malabsorption may
be caused not only by fluorouracil but also by other drugs
affecting cell proliferation such as thioguanine, methotrex-
ate, vinca’s alkaloid, actinomycin D, hydroxyurea and
daunomycin [6].
2. Influence of nutritional deficiencies on
chemotherapy and vice versa
Trace elements consist mostly of metal ions which act mainly
as basic components of essential enzymatic systems or pro-
teins that play major roles in the physiology of the gastroin-
testinal tract (Jackson, 1989). Studies suggest that trace
elements serve as cofactors in several metabolic pathways,
and a decrease in their concentration may facilitate the mal-
nutrition process that takes place in cancer patients. Negative
acute-phase reactants such as selenium and zinc are de-
creased in cancer patients, whereas serum levels of copper
are increased. Selenium deficiency may interfere with
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 9 6 –2 9 8 297free-radical-mediated damage. Zinc regulates the function of
cytochromes, stabilizes plasma membranes, reduces lipid
peroxidation and has a role in the detoxification of ammonia.
A deficiency in zinc potentiates the toxicity of other metals
and decreases the plasma values of vitamin A. Supplementa-
tion of these trace elements can delay cachexia with its con-
sequent depression of the immune system, influencing the
neoplastic process and the success of chemotherapy [7].
Cetuximab, a monoclonal antibody against the epithelial
growth factor receptor (EGFR), can induce an inappropriate
urinary excretion of magnesium through the inhibition of
reabsorption of magnesium in the ascending loop of Henle,
since EGFR is strongly expressed in the kidney [8]. This leads
to symptomatic hypomagnesaemia, a side effect also com-
monly known to be associated with the use of cisplatin.
Cachectic patients with decreased dietary carnitine uptake
may develop carnitine deficiency when treated repeatedly
with chemotherapies that include cisplatin. They have a ten-
fold increase in renal carnitine excretion [9].
Pemetrexed, a multitargeted antifolate, is associated with
life-threatening toxicity, especially myelosuppression, if not
administrated after supplementation with folic acid and vita-
min B12. One week prior to commencing pemetrexed, folic
acid (0.5 mg by mouth each day) and vitamin B12 (1 mg by
intramuscular injection every 9 weeks) should be given [10].3. Influence of nutritional supplements on
chemotherapy
More than 80% of the patients with cancer surveyed in 2000 in
the United States reported using complementary and alterna-
tive medicine (CAM) [11]. While the body of literature related
to the use of CAM is growing, the extrapolation and applica-
tion to patient care remain complex. Clinicians must estab-
lish whether the supplement is an antioxidant, is an
anticoagulant or procoagulant, has immunosuppressive or
immunomodulatory properties, has hormonal properties,
has known safety issues and has known or theoretical drug
interactions [12].
Antioxidants represent one of the largest categories of die-
tary supplements. Reactive oxygen species (ROSs) are a natu-
ral consequence of living in an aerobic environment.
Oxidative stress occurs when natural defence systems are
inadequate to combat the production of ROSs. Antioxidants
could be protective against the adverse effects of chemother-
apy, but some of these agents rely for their antineoplastic
activity on the production or interaction with ROSs. Agents
with a high reliance on ROSs for their antineoplastic activity
are alkylating agents and mitomycin C. Mitoxanthrone is less
likely to be dependent on ROSs.
The use of dietary supplements with anticoagulant proper-
ties, alone or concomitantly with conventional anticoagulants
or antiplatelet medication, may pose a risk for bleeding due to
additive or synergistic effects on the coagulation pathway.
Agents with coumarin constituents – such as angelica root,
agents that inhibit platelets such as panax ginseng, agents
with salicylate constituents such as black cohosh, garlic, gink-
go, saw palmetto – may increase the risk of bleeding. Supple-
ments with procoagulant properties should be avoided withhormonal treatments such as tamoxifen, andwith erythropoi-
etic growth factors, estramustin or thalidomide.
4. Conclusion
Nutrition and nutritional status are influenced by the pres-
ence of cancer but also have an important influence on anti-
cancer treatment and treatment outcome. It is important that
the oncologist has an insight into the possible interactions
and complications that nutritional agents may havewith che-
motherapeutic agents.
The ability to identify and locate reliable information
regarding dietary supplements is vital.
The use of more than one reference is necessary to com-
plete the analysis of dietary supplements for a patient. Coun-
selling patients with cancer about dietary supplements
requires a systematic thought process that considers the
available theories and data, as well as the patient’s views
about these agents [13]. More attention should be paid to pa-
tient nutritional status, and cooperation with a dietician is
essential in the care of the cancer patient.
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